Microbial (Pro)TGase

Recombinant microbial (bacterial) transglutaminase


(MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis)

Order
Quantity
Price
Status
25 U 270 € available
250 U (1 vial) 2140 € available
10 x 25 U 2140 € available
500 U (1 vial) 3750 € available
20 x 25 U 3750 € available


Documents
Art. No. T001
Synonym EC 2.3.2.13, MTG, Protein-glutamine-γ-glutamyltransferase
Background info Transglutaminases are a family of enzymes that catalyze the posttranslational modification of proteins by inserting an isopeptide bond within or between polypeptide chains. These
enzymes catalyze the acyl transfer reaction between the γ-carboxyamide groups of peptidebound glutamine residues and a variety of primary amines, particularly the ε-amino group of lysine. The resulting crosslink is of great significance, since it is highly stable and also resistant to mechanical and proteolytic degradation.

Microbial Transglutaminase by Zedira
Molecular Weight 38,333 Da (Dispase-activated MTG with N-terminal sequence: FRAPDSDDR...)
Source Recombinantly produced in E. coli.
No material of animal origin is used within production process. Gene derived from Streptomyces mobaraensis.
Purity > 95 % (SDS-PAGE)
Specific Activity > 25 U/mg [One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid.
Reagents The purified transglutaminase is lyophilized from 50 mM NaOAc pH 5.0 + 0.3 M NaCl.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves.
Reconstituted MTG solution might be turbid. However, MTG activity is not affected. In this case, centrifuge the solution and collect the supernatant.
After reconstitution, the solution should be stored frozen in working aliquots.
Application Labeling, immobilisation, conjugation and modification of proteins.
MTG can tolerate up to 10% DMSO in aqueous solutions without significant influence on its catalytic activity. A small activity loss of 4% was observed in the presence of 20% DMSO.
Storage Store at –20°C in working aliquots. Repeated freezing and thawing is not recommended.
Delivery is possible at ambient temperature.
Reference(s)

Spycher et al., ChemBioChem 2017, 18:1923-7
Steffen et al., J. Biol. Chem. 2017, 292:15622-35
Dennler et al., Chembiochem. 2015, 16:861-7
Dennler et al., Bioconjugate Chem. 2014, 25, 569-78
Kaufmann et al., Food Addit. Contam. Part. A 2012, 29:1364-73
Jeger et al., Angew. Chem. Int. Ed. Engl. 2010, 49:9995-7
Gianfrani et al., Gastroenterology 2007, 133:780-9
Pfleiderer et al., Microbiol. Res. 2005, 160:265-71
Ando et al., Agric. Biol. Chem. 1989, 53:2613-17
Pasternack et al., Eur. J. Biochem. 1998, 257:570-6
Grossowicz et al., J. Biol. Chem. 1950, 187, 111-25

Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA